The Animal Health Trust reports that a DNA test it developed in 2015 for primary open angle glaucoma (POAG), a painful condition which eventually leads to blindness in the Petit Basset Griffon Vendeen, appears to have stamped out the disease.

When the Newmarket-based veterinary and scientific research charity launched the test, it was believed that one in twenty Petit Basset Griffon Vendeen puppies would grow up to be affected by POAG.

Three years later, through responsible breeders using the DNA test, the AHT says there have been NO affected puppies in the UK reported to The Kennel Club.

The AHT says the test results demonstrate how appropriate DNA testing can lead to the immediate disappearance of a recessive disease, improving the health and wellbeing of countless dogs and their families. 

One breeder who has seen first-hand the benefits of this DNA test is Viv Phillips, who said: "As the breeder who first announced I had a dog affected by POAG I was delighted to work with the AHT and Prof Peter Bedford for 18 years in the research into this disease. I know how tough it is to not be able to avoid your dog going blind at a relatively young age. When the AHT discovered the DNA mutation in November 2014 which was subsequently launched at Crufts in 2015 it was the most wonderful result.

"I tested the PBGVs I still had, including their older parents, and was able to ascertain that puppies I had bred were either at no risk of going blind or sadly carried the gene and therefore treatment could be started to prolong their eyesight. Since this time I have bred 12 puppies and I am delighted that I know they will not be affected as a result of using the DNA test.

"Worldwide approximately 1800 Petit Basset Griffon Vendeen have been tested, and in the UK no puppies have been recorded as affected in the last three years. It is not a numerically large breed and if we can continue to spread the word worldwide and convince breeders to test their breeding stock, we can - with the help of the AHT - look forward to eliminating this awful disease completely."

Dr Cathryn Mellersh, Head of Canine Genetics at the AHT, said: "Years of work went into developing this DNA test which makes it even more rewarding to see it used so well to stop these lovely dogs from going blind. Glaucoma is a very debilitating and painful disease and some dogs have to their eyes removed as a result.

"We are studying glaucoma, and many other blinding diseases, in lots of dog breeds. These mutations can also affect cross bred as well as purebred dogs, so as the popularity of cross bred dogs continues to rise, DNA health testing is more important than ever to make sure you’re breeding, or buying, puppies that are going to have the very best start in life. Great things can be achieved through genetic research and as humans suffer many of the same diseases as dogs, there is always the possibility that our research is going to help human medicine as well. Unfortunately research is expensive and we always need more funding to be able to continue to maintain and expand our research of inherited diseases, including more complex diseases, such as epilepsy."

Defra has released new data showing that new outbreaks of bovine TB have fallen in the two areas that have now completed their licensed four-year badger culls.

In the Somerset cull area, TB incidence has fallen from 24% before culling started to 12% in year four of the cull, while in Gloucestershire it has fallen from 10.4% to 5.6%.

The Government says the findings are in line with expectation based on the scientific evidence from the Randomised Badger Culling Trial which underpins the approach to tackling bovine TB – and demonstrate progress is being made in delivering the 25-year TB eradication strategy in England to rid our farmers of the impacts of this terrible disease.

Defra has also announced additional measures being taken to help control the disease, including licences for badger control in 11 new areas and the opening of a new round of applications for the Badger Edge Vaccination Scheme grants.

Farming Minister George Eustace said: "Bovine TB remains one of the greatest animal health threats to the UK. There is no single measure that will provide an easy answer which is why we are committed to pursuing a wide range of interventions to protect the future of our dairy and beef industries and eradicate the disease within 20 years.

"No one wants to be culling badgers forever so the progress reported today is encouraging."

BVA President John Fishwick said: "We continue to support a comprehensive and evidence-based approach to tackling bovine TB, including the use of badger culling in a targeted, effective and humane manner. TB is a devastating disease and we welcome the positive results emerging in Somerset and Gloucestershire, where licensed culling has now been in place for four years. The recent results in Dorset, indicating a slight upward trend in the incidence of bovine TB, present some cause for concern and we would like to see further investigation of the cattle and wildlife situation in that area.

"BVA supports the principle of badger controls within the Low Risk Areas (LRAs) of England where there is a demonstrated need and where it is done safely, humanely and effectively as part of a comprehensive strategy. We are largely reassured by the greater clarity provided on the decision-making process on how and where badger controls will be introduced in the LRAs. We recognise the expertise and professional judgement of veterinary and scientific colleagues in government who have made the decision to extend the cull in this area, but we would welcome further evidence regarding the level of TB infection in the wildlife reserve in Cumbria as this becomes available.

"Halting the spread of bovine TB is essential and it is vital that we use every available tool in the toolbox to support the Government’s aim to make England TB free. We therefore welcome both the introduction of tighter cattle controls where needed and the re-commencement of the Badger Edge Vaccination Scheme, particularly if used as a ‘firebreak’ to mitigate the spread of the disease into the low risk areas. We would also like to see a commitment to funding of further research in this area."

Photo: Coatesy/Shutterstock

In the week that the National Office of Animal Health has revealed significantly greater levels of pessimism in the animal medicines industry over the impact of Brexit on public health and food production, the BVA also reports that the Department for Exiting the European Union (DExEU) has prevented Defra from consulting the profession over the predicted shortage of veterinary surgeons post-Brexit.

NOAH's third Brexit Barometer found that where in the last report, 17% of its members reported feeling 'very' or 'somewhat pessimistic', that figure has now risen to 32%.

Meanwhile, the National Audit Office has revealed in its 'Progress in Implementing EU Exit' report that Defra has been prevented from consulting with the veterinary market by DExEU.

The report states that Defra is one of the government departments most affected by EU Exit and looks in detail at four of Defra’s main workstreams, including ‘import of animals and animal products’ and ‘exports of animals and animal products’.

In an accompanying press release, the National Audit Office notes that in a no-deal scenario there will be a significant increase in certificates needing to be processed by veterinary surgeons. It says: "Without enough vets, consignments of food could be delayed at the border or prevented from leaving the UK. Defra intended to start engaging with the veterinary industry in April 2018, but has not been permitted to do so and now plans to launch an emergency recruitment campaign in October to at least meet minimum levels of vets required. It plans to meet any remaining gaps through the use of non-veterinarians to check records and processes that do not require veterinary judgement."

The BVA says it has previously outlined concerns about the potential for diluting veterinary certification, and is calling on the Government to fully engage with the veterinary profession before making any changes that could impact the UK’s ability to trade animal products safely and in line with high animal welfare standards.

The RCVS has also weighed in. Amanda Boag, RCVS President, said: "We are glad to see the National Audit Office report recognises that a ‘no deal’ Brexit scenario would be likely to reduce the supply of EU veterinary surgeons to the UK and cause uncertainty regarding the status of those EU veterinary surgeons who are currently living and working in the UK and that this would have a particularly serious impact on necessary veterinary work in public health and certification. 

"We continue to engage with Defra and, like the BVA, we want to emphasise the essential need for Government to consult with the profession to ensure their plans meet requirements, including maintenance of the high veterinary standards for which the UK is known. We also want to highlight the importance and value of the veterinary profession in other areas of society including caring for pets, horses and farm animals as well as research, education and industry, and emphasise the impact of workforce shortages on all sectors."

The Royal Veterinary College has performed world-first surgery to correct a combination of congenital heart defects in a dog that needed a repair to its tricuspid valve and common atrium.

Lottie, an 11-month-old Labrador puppy was found to have a very loud heart murmur during a routine check before being spayed. 

An ultrasound revealed that she had several congenital defects. The two major ones were a malformation of her tricuspid valve and a very large defect of the common atrium.

Lottie was referred to the RVC’s cardiothoracic department where she underwent further ultrasound and a CT scan. The team at the RVC, which is led by Dan Brockman, Professor of Small Animal Surgery, had already performed several cutting-edge surgeries, including a world-first treatment to save the life of a dog born with a malformed tricuspid valve.

Repair of the tricuspid valve has only been performed a handful of times and has not been done at the same time as repair of a common atrium. 

Lottie’s owners decided to proceed with the operation, which was undertaken at the end of July. Lottie's heart was stopped for the procedure and her circulation maintained with a heart lung machine run by perfusionist Nigel Cross from Great Ormond Street Hospital.

Poppy Bristow, Fellow in Cardiothoracic Surgery at the RVC, said: "Altogether 10 people were involved in her operation and many more for her care before and after surgery, including veterinary specialists, veterinary nurses and veterinary specialists-in-training from surgery, cardiology, anaesthesia and emergency and critical care, as well as Lottie’s referring cardiologist and her local veterinary practice. 

"Lottie’s heart was stopped for an hour and a half, with the whole operation taking four hours. Her malformed tricuspid valve was released by cutting its abnormal attachments and artificial chords using Gore-Tex material were placed. Her single atrium was then divided into two using a large patch of Gore-Tex. Lottie has made a good recovery so far and was walking around and eating from the day after her surgery. She was discharged back to her owners after six days and has continued to thrive at home."

Professor Brockman added: "In Lottie, we had a young energetic dog with such a serious and life-limiting heart condition, that we were desperate to try and help her. The repair was complex but incorporated a combination of surgical manoeuvres that we had done before. With careful pre-operative planning and using our previous experience, we were able to design and execute the surgical treatment. It is still ‘early days’ but the initial signs suggest that Lottie is going to enjoy an excellent quality of life, following this operation and, we all hope, a normal lifespan."

Fitzpatrick Referrals has been joined by Dr Michael Macfarlane as Senior Clinician in Medical Oncology. 

Michael qualified from the University of Glasgow in 2009 and then worked in first opinion practice in Buckinghamshire and Northern Ireland. He then returned to the University of Glasgow in 2012 to further his training and experience in oncology by completing four years of additional training. He completed an ECVIM residency in oncology in 2016 and became a Diplomate of the European College of Veterinary Internal Medicine and a European Specialist in Oncology in 2017. Michael worked at a private referral practice in Surrey prior to joining Fitzpatrick Referrals. Earlier this year, Michael was awarded a Masters degree in Veterinary Medicine. This additional qualification researched canine mast cell tumours.

Michael said: "I am absolutely delighted to have joined Fitzpatrick Referrals Oncology and Soft Tissue hospital. I have had a long-standing ambition to work as part of the fantastic team here since visiting the hospital during my specialist training in 2015. At this visit, I immediately felt at home in a group of people driven to deliver the very best compassionate care for dogs and cats.

"My ambition is to develop the very best ways to minimise the impact that cancer has on animals. I know that Fitzpatrick Referrals is the best environment for me to be able to achieve this. Throughout the hospital, there is an amazing positive attitude and a collective drive to improve the overall care we can give to pets with cancer. I am also excited by the opportunity to be able to help others to achieve their goals in improving cancer care for pets."

The RCVS Disciplinary Committee has decided to suspend overseas-based James Hugh Alexander Crawford MRCVS for a period of 12 months, after he fabricated an email, purporting it to be from a veterinary officer at the Animal Health and Veterinary Laboratories Agency (AHVLA), now known as the Animal and Plant Health Agency.

Dr Crawford sent the email to his client, Mrs X, on 15 July 2014, the day on which Mrs X’s horse was due for insemination using horse semen supplied from a horse in Germany. However, the semen had arrived without the Intra Trade Certificate, a requirement for intra-EU inseminations, and so Dr Crawford proceeded to contact the Department for the Environment, Food and Rural Affairs (Defra) for alternative authorisation.

Just after 4:30pm on that day, Mrs X received a text from Dr Crawford advising her that he had received authorisation from the AHVLA, and would forward to Mrs X the AHVLA authorisation email. It later transpired that that the email had in fact been fabricated by Dr Crawford using an email that he had previously received from the AHVLA regarding another matter.

Dr Crawford faced the following charges:

1. Fabricating an e-mail purporting to be from the veterinary officer at the AVHLA, authorising use of semen from a horse for insemination, when in fact he had not received such authorisation.

2. Dishonesty in relation to the e-mail described above.

3. His conduct gave rise to spread of infectious disease which had the potential to affect equine animal health and welfare in the region.

Dr Crawford admitted the first two charges, but denied that his actions had given rise to the risk of disease.

The Committee found the first two charges proved, and moved on to determine the facts of the third charge. They took into account that Dr Crawford had received verbal confirmation that the semen was safe, and that the health papers had been stamped accordingly. He had not, however, seen a copy of this certificate and so there was no guarantee that the semen was safe to use at the time he sent the fabricated email. On consideration of the facts, the Committee found this charge proved, as Mrs X’s mare could have been infected and subsequently could have adversely affected equine animal health and welfare in the region.

They also found that his entire course of action had fallen far short of what is expected of a veterinary surgeon, and that it amounted to disgraceful conduct in a professional respect. 

When determining sanction, the Committee took into account a number of aggravating factors, namely the risk of injury to animals, an element of pre-meditation, a disregard for the role of the AHVLA, impersonating a fellow veterinary surgeon, and intending to deceive a veterinary surgeon as well as a member of the public.

It did also, however, take into account the mitigating factors – that there was no injury to the animal, and that it was a single isolated incident from which Dr Crawford did not stand to make any financial gain.

The Committee therefore decided to order the Registrar to suspend Dr Crawford’s registration for 12 months.

Ian Green, chairing the Committee and speaking on its behalf, said: "The Committee did consider whether to remove Dr Crawford from the Register. However, in light of the significant mitigation in this case, the fact that this was an isolated incident in an otherwise unblemished career, together with his acceptance from the outset that he had been dishonest and his assurance that he would never behave in this way again, the Committee decided that in all the circumstances to remove him from the Register would be disproportionate."

Dr Crawford can lodge an appeal with the Privy Council within 28 days of being notified of the Disciplinary Committee's decision.

Leading veterinary dermatologist Sue Paterson has raised concerns that veterinary surgeons are not prioritising pain relief in otitis externa (OE) cases, in a new series of videos commissioned by Elanco Animal Health for Osurnia Gel.

Sue, an RCVS and European Specialist in Veterinary Dermatalogy and Senior Vice President of the European Society of Dermatology, says the failure to prioritise pain relief is having a "profound effect on the quality of life of both dogs and clients."

Sue is urging vets to think about the impact that pain has on both the dog and owner in cases of OE: "Otitis externa is painful, it’s debilitating, and the degree of discomfort is often underestimated by both the veterinary surgeon and by the client."

Sue also says vets should not underestimate the owner’s concern about pain in their dog. Owners recognise the clinical signs associated with the pain of OE and determine treatment success by their dog recovering from these distressing symptoms.

To help manage the pain associated with OE, Sue recommends a multi-modal approach: "In addition to systemic pain relief, which is really important, a potent topical steroid is really useful to reduce the inflammation inside that dog’s ear, and make it much more comfortable."

Sue also highlights OE treatments which are able to coat the ear canal and stay there long enough to treat the pathogens and provide sustained pain relief: "When you put it into the ear, Osurnia Gel coats the lining of the external ear canal which gives prolonged contact with the lining of the canal to help treat the pathogens inside that dog’s ear."

Elanco says that despite Osurnia entering the market two years ago, some vets are still saving it for difficult cases. Sue said: "Too many vets use this [Osurnia] as a second-line drug and it should be used as a first-line product on the first occasion the dog comes through the door."

To watch the full series of videos and to find out more from Sue Paterson on treating otitis externa in dogs, visit: www.Osurnia.co.uk

VetSurgeon.org has launched a competition in which the veterinary surgeons who submit the best professional 'top tips': those that could make life easier, quicker, better or happier for a colleague in the profession, will win a £50 Amazon voucher.

Your tip could be clinical in nature (perhaps specific to a particular discipline, like cardiology or exotics), or to do with practice management, or dealing with clients, or HR, or, well, anything really.

To enter the competition, login to VetSurgeon.org and submit your tip in the forum, here.

Just before you press the button to post your tip, you might like to tick the box marked: "EMAIL ME REPLIES TO THIS POST" which appears immediately above the post button. That way, you'll get an email when someone else posts a tip.

Above each post in the forum, there is now a 'Thank You' link, which allows members to express their thanks for sharing something. The five tips that generate the largest number of 'thank yous' by the end of November will win the Amazon vouchers.

VetSurgeon.org is all about facilitating the sharing of knowledge, ideas and experience. So any tip entered into the competition will also be disseminated, together with the contributor's name, on other social media channels, such as Facebook, Twitter, Linkedin and if you include a photo, on Instagram.

VetSurgeon.org Arlo Guthrie said: "The competition is really designed to show off the new 'thank you' feature on VetSurgeon, which allows members to show their appreciation when someone shares something useful with their peers. In due course, we'll be running similar competitions for the most thanked photos and videos uploaded to our galleries. Watch this space."

Researchers at the Royal Veterinary College report that they've made a significant breakthrough in the search for a durable treatment for Duchenne muscular dystrophy (DMD).

Working in collaboration with researchers at University of Texas, Southwestern (UTSW) Medical Center, the team has succeeded in using gene editing techniques on dogs to restore the expression of the dystrophin protein that is absent in DMD patients’ muscles to levels that could be life changing.

DMD is the most common, fatal, genetic disease that affects children. The same disorder also occurs in many dog breeds. It is caused by mutations in the gene that encodes dystrophin, a crucial protein that helps protect muscle fibres and the heart when they contract. Patients with the disease produce effectively no dystrophin protein, so their muscles and heart become damaged during contraction, leading to inability to walk, skeletal deformities, breathing problems and heart failure. Patients with DMD have a life expectancy that does not go far beyond their twenties.

Researchers say that this preliminary research, published in Science, demonstrates an approach that could lead to an effective, in principle one-time treatment for DMD for the most common genetic mutations affecting human patients. Through a single intravenous injection, researchers have been able to modify the dystrophin gene in many muscles of the body, including the heart, with the result that some muscles now had almost the normal amounts of dystrophin protein.

The team, led by Eric Olson, Ph.D., professor and chair of the Department of Molecular Biology at UTSW Medical Center and founder and chief science advisor of Exonics Therapeutics, and Richard Piercy, Ph.D., MRCVS, Professor of Comparative Neuromuscular Disease at the RVC, identified a naturally-occurring mutation in the dystrophin gene in a dog brought to the RVC’s Small Animal Referral Hospital.

Working now with relatives of this first dog, the combined group has used a technique called ‘SingleCut CRISPR gene editing’, where the researchers target a specific region of the subject’s own DNA. Harmless viruses encoding the gene-editing protein CRISPR/Cas9 were used to express the enzyme in muscle to cut the dogs’ own DNA at a precise location in the dystrophin gene through use of a molecular guide. The body’s own processes then repair the cut, which results in removing the negative effects of the existing mutation.

The researchers have demonstrated that dogs treated in this way had restored ability to produce large amounts of the dystrophin protein in their muscles and heart, and in the dog with the highest dose, cardiac muscles were found to have restored dystrophin protein to up to 92% of normal amounts after the single treatment.

The team believes this is the first time that this form of gene editing therapy has been conducted after birth in an animal larger than a rodent. With further longer-term research, efficacy and safety testing, it is hoped that this breakthrough will have human application. This treatment may be a significant step toward developing a gene editing therapy to repair genetic mutations for DMD, as well as a range of diseases caused by genetic mutations.   

Richard Piercy, Professor of Comparative Neuromuscular Disease at the RVC, said: "Researchers have been looking for an effective and durable treatment for Duchenne muscular dystrophy for many years. This SingleCut gene editing approach, pioneered by Dr. Eric Olson’s group, has the potential to be a one-time treatment that could restore dystrophin protein. It is hugely exciting that through a single intravenous injection we’ve been able successfully to modify the dogs’ own DNA so they start generating dystrophin protein again. There is more work to be done, but with this exciting breakthrough, we feel we are a significant step closer to finding an effective treatment.

"A great many genetic diseases affect humans, dogs and other species - many, like DMD - with tragic consequences and this form of gene editing treatment might well be applicable in many of them. We’re hopeful that we’re paving the way for future research into treating some of the most serious genetic conditions that affect us today."

The BSAVA has announced the publication of a fully revised Manual of Canine and Feline Dentistry and Oral Surgery, including the most relevant, evidence-based, step-by-step operative techniques, and full-colour illustrations and photographs.

Alexander Reiter and Margherita Gracis formed the new editorial team and selected an international collection of leaders in their fields of expertise to contribute to this latest edition.

Alexander said: "This is a timely publication, as veterinary dentistry is a field that continues to grow in importance for the general veterinary practitioner. We found it important to add 'Oral Surgery' to this new edition, as many procedures performed in and around the mouth involve surgical techniques."

The BSAVA Manual of Canine and Feline Dentistry and Oral Surgery, 4th edition, is an accessible source of core information for general small animal veterinary surgeons, nurses/technicians and students interested in developing their theoretical knowledge and practical skills in dentistry and oral surgery.

The manual is now available from the BSAVA website (www.bsava.com/shop), the BSAVA Library (www.bsavalibrary.com/manuals), or by phone: 01452 726700.

Norbrook has announced the launch of Moxiclear, a monthly spot-on broad spectrum endectocide for the treatment and prevention of parasites in dogs, cats and ferrets.

Moxiclear contains moxidectin and imidacloprid.

In dogs, Moxiclear can be used for the treatment and prevention of flea infestations and as part of a treatment plan for flea allergic dermatitis. It is also indicated for lungworm, ear mites, sarcoptes mites, biting lice, round worm, hookworm, whipworm, skinworm, and prevents heartworm.

In cats, Moxiclear can be used for the treatment and prevention of flea infestation and flea allergic dermatitis, as well as ear mite infestations. It is also indicated for notoedric mange, gastrointestinal nematodes; whipworm, roundworm and hookworm, and for the prevention of heartworm disease.

In ferrets, Moxiclear can be used to treat and prevent flea infestation, and prevent heartworm.

Moxiclear is available for 4kg-40kg dogs, with four pipette fill sizes. Small cats and ferrets weighing less than 4kg are catered for with a 0.4ml pipette. Large cats weighing 4-8kg can be treated with the Moxiclear 0.8ml pipette.  

Lorron Bright, Norbrook Product Manager, said: "Moxiclear offers good value, broad-spectrum parasite control for dogs, cats and ferrets. This latest launch provides our customers with an excellent value, alternative choice for a imidacloprid/moxidectin product."

Richard Palmer, Norbrook Global Head of Sales and Marketing, said: "Moxiclear spot-on is the 11th product we have launched in the past three years. Six of the new products are in the companion animal sector as we continue to strengthen our foothold in the growing global companion animal market. Norbrook is committed to delivering a strong new product pipeline, along with our multi-year £50 million investment programme."

The RCVS Disciplinary Committee has found Cheshire-based Paul Stuart Thomason MRCVS not guilty of disgraceful conduct after hearing charges that he undertook a pre-purchase examination of a horse called Reba which caused him to have a potential or actual conflict of interest with the seller, about which he failed to inform the prospective buyer.

Dr Thomason initially denied both heads of charge, but on the third day of the hearing he changed his plea and admitted the charge in its entirety.

The first part of the charge related to the fact that the seller of the horse was a both a client of Dr Thomason’s practice and a personal friend of his, and he therefore had a potential and/or actual conflict of interest.

Dr Thomason did not disclose this professional and personal relationship to the prospective purchaser before the pre-purchase exam.

The prospective purchaser only discovered Dr Thomason’s relationship with the seller when reading the vetting certificate at home, and stated that, in the past, she had had a similar experience in which the horse was then found to be lame. She later found out the extent of the personal relationship, when invited to join the seller on a social media site.

The Committee found that, in this set of circumstances, Dr Thomason should not have undertaken the pre-purchase exam at all, and, at the very least, disclosed his personal and professional relationship with the vendor.

The Committee also found that although Dr Thomason did have a system in place to inform any prospective purchasers if the vendor was a client of his practice, this failed to work on this occasion and neither the practice nor Dr Thomason told the prospective buyer that the seller was a client before booking the pre-purchase exam. Dr Thomason had no similar system in place to disclose any close friendships with sellers.

Dr Thomason did not consider there was a conflict of interest as he felt confident he could carry out the pre-purchase exam impartially. In addition, it was his belief that the seller had been alerted to the conflict through a system in place at his practice, implemented to safeguard against this type of error. He stated that he in no way attempted to hide his relationship with the seller to the prospective purchaser. 

It was not alleged that Dr Thomason had acted dishonestly.

Ultimately, the Committee found Dr Thomason not guilty of disgraceful conduct in a professional respect.

Ian Green, chairing the Committee and speaking on its behalf, said: "Whilst the Committee concluded that the respondent’s view of his obligations to disclose both the professional and personal relationships he had with the vendor was mistaken, it did not find any improper motivation on his part. It has already noted that he sought to disclose to the prospective purchaser through his system the fact that the vendor was a professional client of his.

"The Committee has weighed all these matters very carefully. It is for the client to determine whether or not to proceed with a PPE when in possession of all relevant facts in relation to any potential conflict of interest, and not for the veterinary surgeon to decide. The autonomy of the client must be respected. The Committee was firmly of the opinion that a failure to comply with the Code is very serious. However, taking into account the particulars of this case, the Committee does not consider that the actions of the respondent amount to disgraceful conduct in a professional respect."

Enteromed has launched EnteroZoo, a new drug-free adsorbent gel for use in animals or birds suffering from a range of gastrointestinal problems including dyspepsia, ulcers and poisoning.

EnteroZoo is a dietary supplement composed of organic mineral and purified water in a gel suspension. Enteromed says it works by binding bacterial toxins as it passes through the animal's digestive tract, thereby helping to maintain a healthy gut and intestinal balance.

Enteromed says that compared to old classic adsorbents, such as clay or charcoal, EnteroZoo can be used long-term and is gentle on an animal's intestines.

The company points to a new in-vitro study from Brighton University School of Pharmacy & Biomolecular Sciences which has shown that EnteroZoo adsorbs E. coli, Shigella and C. difficile toxins¹ – common causes of gastrointestinal infection and diarrhoea.

EnteroZoo is suitable for all animals including pregnant and nursing females. It is tasteless and odourless and the company says animals generally accept it without any problems. It can be administered in various ways: directly into the mouth, mixed into feed, put on a treat, mixed in an appropriate amount of water or administered with a plastic syringe into the oral cavity.

For more information, contact:  enterozoo@enteromed.co.uk, or visit: www.enterozoo.co.uk

Reference

1. Dr Carol Howell, ‘Enterosgel removal of Cdiff toxin B and Endotoxin’, School of Pharmacy & Biomolecular Sciences, University of Brighton, 2017.